01/ 04
Connect evidence
Connect the selected runs to their cell banks, seed lots, infection conditions and assay methods.
01
← All modalities
VAX · CELL CULTURE
Viral vaccines
Connect cell-bank and seed-virus genealogy with infection conditions, titre trajectories, harvest, downstream recovery and inactivation evidence. Compare viral-vaccine runs in their assay and process context to plan the next study.
VAX · Cell cultureViral vaccines
OUTCOMES TRACKEDInfectious titrecell-specific yieldrecovery
MODALITY-SPECIFIC PROCESS INTELLIGENCE
Follow infection biology through harvest and quality review.
01Cell bank & seed
02Infection
03Harvest & recovery
04Inactivation & quality
FOCUS AREA · Cell bank & seed
Cell bank and seed virus
Trace host-cell banks, seed-virus lots, passage levels and recorded qualification state into each production run.
01
EVIDENCE · MODELS · DECISIONS
Keep every conclusion connected.
Evidence in Bio Hub
- Cell-bank, seed-virus lot and passage genealogy
- MOI, infection timing, cell density and culture time series
- Infectious titre, particles, antigen and viability assays
- Downstream recovery, inactivation and lot-testing records
Models in Bio Twin
- Data-driven titre trajectories with held-out run evaluation
- Mechanistic infection scenarios with an eclipse phase
- Harvest timing and infection-condition comparisons
- Log-scale recovery and inactivation calculations
Scientific decisions
- Compare infection conditions and harvest windows
- Balance infectious titre, viability and recovery
- Review inactivation evidence and analytical gaps
- Prepare traceable evidence for expert quality review
Process outcomes to evaluate: Infectious titre · cell-specific yield · recovery
EXAMPLE INVESTIGATION
Does a later harvest deliver more usable viral product?
02/ 04
Compare context
Compare infectious titre trajectories, particle-to-infectivity ratio and viability at candidate harvest times.
02
03/ 04
Evaluate explanations
Review downstream recovery and, where applicable, inactivation evidence alongside the harvest comparison.
03
04/ 04
Review next steps
Prepare the evidence-linked study proposal, analytical gaps and acceptance criteria for Process Development, Analytical, MSAT and Quality review.
04
Bio Agents can coordinate the scientific work across evidence and models, while Bio OS preserves governance and human review. The configured workflow determines which tasks and models are available.
Bring us this process challenge ↗EVALUATION & SCOPE
Make the demonstration specific.
This workflow covers cell-culture viral vaccines. Confirm the host, virus, product type, assay basis and intended decision before evaluation. Data-driven predictions require adequate project data and held-out validation; mechanistic infection scenarios use literature parameters and are not project-calibrated. Recorded inactivation and lot-testing comparisons support expert review; they do not establish validated viral clearance, vaccine efficacy or batch-release authorization.
What evidence should we bring?
Cell-bank, seed-virus lot and passage genealogy. MOI, infection timing, cell density and culture time series. Infectious titre, particles, antigen and viability assays. Downstream recovery, inactivation and lot-testing records. Include the process question, relevant run context and the analytical methods used to assess the outcome.
How do models support the workflow?
Data-driven titre trajectories with held-out run evaluation. Mechanistic infection scenarios with an eclipse phase. Harvest timing and infection-condition comparisons. Log-scale recovery and inactivation calculations. Scope and evaluation criteria are defined for your process, data and intended decision.
What should we validate before using the results?
This workflow covers cell-culture viral vaccines. Confirm the host, virus, product type, assay basis and intended decision before evaluation. Data-driven predictions require adequate project data and held-out validation; mechanistic infection scenarios use literature parameters and are not project-calibrated. Recorded inactivation and lot-testing comparisons support expert review; they do not establish validated viral clearance, vaccine efficacy or batch-release authorization.
EXPLORE OTHER MODALITIES
ENTERPRISE USE CASE
Investigating vaccine harvest and recovery variability
Connect campaign, assay and recovery evidence to separate an upstream signal from a downstream loss or measurement difference.
Explore the complete use case ↗